Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor

Keyphrases

• Behavioral Effects 100%
• Neurochemicals 100%
• Dopamine Reuptake Inhibitor 100%
• Serotonin-norepinephrine Reuptake Inhibitors 100%
• IC50 27%
• Excessive Daytime Sleepiness 27%
• Obstructive Sleep Apnea 27%
• Narcolepsy 27%
• Dopamine 18%
• Dopamine Transporter 18%
• Amphetamine 18%
• Norepinephrine Transporter 18%
• Promoting Effect 18%
• Wake-promoting 18%
• Clinical Application 9%
• Preclinical Data 9%
• Microdialysis 9%
• Clinical Data 9%
• Mechanism of Action 9%
• Neurotransmitter Systems 9%
• Functional Activity 9%
• Sleep Disorders 9%
• U.S. Food 9%
• Histamine 9%
• In Vivo Assay 9%
• Methylphenidate 9%
• Serotonin Transporter 9%
• Monoamines 9%
• Monoaminergic System 9%
• Monoamine Transporters 9%
• In Vivo Effects 9%
• Release Properties 9%
• Extracellular Concentration 9%
• Orexin 9%
• Uptake Inhibition 9%
• Dual Activity 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Behavioral Effect 100%
• Dopamine Reuptake Inhibitor 100%
• Norepinephrine Reuptake Inhibitor 100%
• IC50 27%
• Sleep Disordered Breathing 27%
• Somnolence 27%
• Narcolepsy 27%
• Modafinil 27%
• Noradrenalin 18%
• Monoamine 18%
• Noradrenalin Transporter 18%
• Dopamine Transporter 18%
• Amphetamine 18%
• Sleep Disorder 9%
• Neurotransmitter 9%
• Microdialysis 9%
• Histamine 9%
• Orexin 9%
• Methylphenidate 9%
• Serotonin Transporter 9%
• Dexamphetamine 9%
• Armodafinil 9%